



Endologix
Investor Relations Department
2 Musick
Irvine, CA 92618
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: ELGX

Last Trade:	5.44
Trade Time:	4:00 PM ET May 24, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	3.75 - 6.50
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

- **Addressing a signi... [\(more\)](#)**

Stock Performance



Press Releases [\[View all \]](#)

- May 2, 2018*
[Endologix Appoints John Onopchenko as Chief Executive Officer](#)
- May 2, 2018*
[Endologix Reports First Quarter 2018 Financial Results](#)
- Apr 25, 2018*
[Endovascular Aneurysm Sealing \(EVAS\) with Nellix System Associated with Higher Survival than Traditional Endovascular Aneurysm Repair \(EVAR\) in New Study](#)
- Apr 3, 2018*
[Endologix, Inc. to Announce First Quarter 2018 Financial Results on May 2, 2018](#)
- Mar 19, 2018*
[Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair \(EVAR\) Using Ovation Abdominal Stent Graft Systems](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 13, 2018*
[Annual Report \(10-K\)](#)
- May 1, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 9, 2018*
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2017*
[Quarterly Report \(10-Q\)](#)